Holen Sie sich die Stockscreener-App
262.08
1.33%
-3.43
Schlusskurs vom Vortag:
$265.51
Offen:
$261.53
24-Stunden-Volumen:
260.17K
Relative Volume:
0.30
Marktkapitalisierung:
$12.62B
Einnahmen:
$4.03B
Nettoeinkommen (Verlust:
$-182.84M
KGV:
-69.70
EPS:
-3.7603
Netto-Cashflow:
$391.29M
1W Leistung:
+12.71%
1M Leistung:
+14.57%
6M Leistung:
+38.46%
1J Leistung:
+74.92%
1-Tages-Spanne:
$260.82
$266.67
1-Wochen-Bereich:
$228.01
$268.00
52-Wochen-Spanne:
$144.26
$268.00
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
261.99 | 10.80B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
587.54 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.95 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
589.31 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
319.10 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
144.80 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-05-29 | Hochstufung | CLSA | Hold → Outperform |
| 2026-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-17 | Hochstufung | Argus | Hold → Buy |
| 2025-11-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Labs /US Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Charles River Laboratories International Inc (CRL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Charles River Laboratories International Inc - TradingKey
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles River Laboratories International Inc (CRL) Institutional Confidence - TradingKey
TradingKey - TradingKey
CRL|Charles River Laboratories International Inc|Price:228.000|Chg%:+3.700 - TradingKey
Charles River Laboratories International Inc (CRL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRL|Charles River Laboratories International Inc|Price:224.200|Chg%:-2.380 - TradingKey
ETFs Investing in Charles River Laboratories International, Inc. Stocks - TradingView
Charles River Labs stock trades around recent lows as investors weigh 2024 guidance and Discovery se - Ad-hoc-news.de
Charles River Laboratories International (CRL) Could Be 28% Undervalued On Its New Collaboration - simplywall.st
Q3 2025 Charles River Laboratories International Inc Earnings Call Transcript - GuruFocus
Charles River Laboratories International, Inc. Revenue Breakdown – NYSE:CRL - TradingView
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
HCA Q2 Earnings Beat on Strong Admissions, 2026 Outlook Revised - TradingView
CRL|Charles River Laboratories International Inc|Price:226.580|Chg%:-2.740 - TradingKey
Charles River Laboratories International Inc (CRL) Stock Up 4.8% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Charles River Laboratories Gains as Analysts Turn More Constructive Ahead of Earnings - Quiver Quantitative
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
CRL stock steadies as Charles River Laboratories focuses on growth after recent earnings - Ad-hoc-news.de
Charles River Laboratories stock hits 52-week high at $238.46 By Investing.com - Investing.com Nigeria
Charles River Laboratories stock hits 52-week high at $238.46 - Investing.com
Charles River Laboratories International Inc. Stock Advances 4.8%, Outperforms Peers - Bitget
Charles River Labs stock reflects mixed outlook as guidance reset follows scrutiny on Cambodian supp - AD HOC NEWS
CRL4900988 Bond Risk Profile - TradingView
Charles River stock edges higher as guidance and drug development demand frame 2026 outlook - AD HOC NEWS
CRL4900988 Bond Coupon Profile — Rate & Payments - TradingView
Price to sales forward of Charles River Laboratories International, Inc. – NYSE:CRL - TradingView
Charles River Laboratories Earnings Preview: What to Expect - webull.com
Charles River Labs stock steadies as investors weigh recent earnings trends and outsourcing demand - AD HOC NEWS
CRL5145814 Bond Risk Profile - TradingView
CLSA downgrades Charles River Labs stock rating on valuation By Investing.com - Investing.com Nigeria
Charles River Laboratories (CRL): Investor Outlook Reveals Promising Upside Amidst Sector Challenges - DirectorsTalk Interviews
CLSA downgrades Charles River Labs stock rating on valuation - Investing.com
Charles River Labs stock steadies as revenue growth offsets regulatory headwinds - AD HOC NEWS
CRL5145814 Bond Coupon Profile — Rate & Payments - TradingView
Charles River Labs stock trades steady as recent revenue growth and margin trends frame investor foc - AD HOC NEWS
CRL4900987 Bond Risk Profile - TradingView
Charles River Labs stock reflects recent earnings trends and regulatory overhang - AD HOC NEWS
CRL4900987 Bond Coupon Profile — Rate & Payments - TradingView
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now? - Yahoo Finance
How Charles River’s Expanded GMP NGS Role in ALA-101 Testing Will Impact Charles River (CRL) Investors - simplywall.st
Charles River Laboratories International (CRL) Expands Cell Therapy Work, Is The Stock Still Undervalued? - Yahoo Finance
Charles River Labs stock trades steady as recent earnings and guidance frame valuation - AD HOC NEWS
Charles River Labs stock holds support as investors wait for fresh numbers. - Ad Hoc News
Does Arovella CAR-iNKT NGS Partnership Deepen Charles River’s Cell Therapy Moat or Stretch CRL Too Thin? - Yahoo Finance
Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call - BioSpace
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Charles River Laboratories (CRL) to Report Q2 2026 Earnings on A - GuruFocus
Global Clinical Trials Market to Reach $176.32 Billion by 2030 as AI and Decentralized Research Accelerate Growth - GlobeNewswire Inc.
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):